Nascent Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022
For the six months, net loss was USD 1.45 million compared to USD 0.661106 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago. Diluted loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago.